Document Detail

Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement.
MedLine Citation:
PMID:  20083681     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: The cytochrome P450 (CYP) 2C19 isoenzyme plays an important role in clopidogrel metabolization. A recently explored CYP2C19*17 allelic variant has been linked to increased transcriptional activity, resulting in extensive metabolization of CYP2C19 substrates, which may lead to an enhanced platelet response to clopidogrel treatment. The aim of this study was to assess the impact of CYP2C19*17 on ADP-induced platelet aggregation, the risk of bleeding, and stent thrombosis in clopidogrel-treated patients undergoing percutaneous coronary intervention. METHODS AND RESULTS: The study population included 1524 patients undergoing percutaneous coronary intervention after pretreatment with 600 mg clopidogrel. Genotypes were determined with a TaqMan assay. ADP-induced platelet aggregation was assessed on a Multiplate analyzer. The primary clinical safety end point was the 30-day incidence of bleeding defined according to Thrombolysis in Myocardial Infarction criteria, and the primary clinical efficacy end point was the 30-day incidence of stent thrombosis. For both heterozygous (*wt/*17; n=546) and homozygous (*17/*17; n=76) allele carriers, significantly lower ADP-induced platelet aggregation values were found compared with wild-type homozygotes (*wt/*wt; n=902; P=0.039 and P=0.008, respectively). CYP2C19*17 allele carriage was significantly associated with an increased risk of bleeding; the highest risk was observed for CYP2C19*17 homozygous patients (P=0.01, chi(2) test for trend). Multivariate analysis confirmed the independent association of CYP2C19*17 allele carriage with platelet aggregation values (P<0.001) and the occurrence of bleeding (P=0.006). No significant influence of CYP2C19*17 on the occurrence of stent thrombosis was found (P=0.79). CONCLUSIONS: CYP2C19*17 carrier status is significantly associated with enhanced response to clopidogrel and an increased risk of bleeding.
Dirk Sibbing; Werner Koch; Daniela Gebhard; Tibor Schuster; Siegmund Braun; Julia Stegherr; Tanja Morath; Albert Schömig; Nicolas von Beckerath; Adnan Kastrati
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-01-18
Journal Detail:
Title:  Circulation     Volume:  121     ISSN:  1524-4539     ISO Abbreviation:  Circulation     Publication Date:  2010 Feb 
Date Detail:
Created Date:  2010-02-03     Completed Date:  2010-03-11     Revised Date:  2010-10-08    
Medline Journal Info:
Nlm Unique ID:  0147763     Medline TA:  Circulation     Country:  United States    
Other Details:
Languages:  eng     Pagination:  512-8     Citation Subset:  AIM; IM    
Deutsches Herzzentrum München, Lazarettstrasse 36, 80636 München, Germany.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aryl Hydrocarbon Hydroxylases / genetics*,  metabolism
Coronary Artery Disease / therapy*
Coronary Thrombosis / prevention & control*
Follow-Up Studies
Gene Frequency / genetics
Hemorrhage / epidemiology*
Middle Aged
Multivariate Analysis
Platelet Aggregation / genetics*
Platelet Aggregation Inhibitors / therapeutic use
Polymorphism, Genetic / genetics
Risk Factors
Ticlopidine / analogs & derivatives*,  metabolism,  therapeutic use
Treatment Outcome
Reg. No./Substance:
0/Platelet Aggregation Inhibitors; 55142-85-3/Ticlopidine; 90055-48-4/clopidogrel; EC Hydrocarbon Hydroxylases; EC protein, human
Comment In:
Circulation. 2010 Feb 2;121(4):481-3   [PMID:  20083686 ]
Circulation. 2010 Oct 5;122(14):e478; author reply e479   [PMID:  20921447 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arterial stiffness and cardiovascular events: the Framingham Heart Study.
Next Document:  Uncoupled cardiac nitric oxide synthase mediates diastolic dysfunction.